• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Steel Dynamics Set To Join S&P 500 Replacing Abiomed; Super Micro Computer To Join S&P MidCap 400 Replacing Steel Dynamics

    12/19/22 5:17:51 PM ET
    $ABMD
    $JNJ
    $SMCI
    $STLD
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABMD alert in real time by email

    S&P MidCap 400 constituent Steel Dynamics Inc. (NASD:STLD) will replace Abiomed Inc. (NASD:ABMD) in the S&P 500 and Super Micro Computer Inc. (NASD:SMCI) will replace Steel Dynamics in the S&P MidCap 400 effective prior to the opening of trading on Thursday, December 22. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Abiomed in a deal expected to close soon pending final conditions.

    Get the next $ABMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABMD
    $JNJ
    $SMCI
    $STLD

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    Super Micro Computer Inc.
    $SMCI
    1/13/2026$26.00Sell
    Goldman
    Steel Dynamics Inc.
    $STLD
    1/9/2026$194.00Overweight → Equal-Weight
    Morgan Stanley
    Johnson & Johnson
    $JNJ
    11/13/2025$230.00Sector Outperform
    Scotiabank
    Super Micro Computer Inc.
    $SMCI
    11/6/2025Hold → Buy
    Argus
    Steel Dynamics Inc.
    $STLD
    11/4/2025$165.00Buy → Neutral
    UBS
    Johnson & Johnson
    $JNJ
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    Johnson & Johnson
    $JNJ
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $ABMD
    $JNJ
    $SMCI
    $STLD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

    Johnson & Johnson (NYSE:JNJ) will present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10th, 2026. Management will participate in a Fireside Chat at 11:30 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20260209671111/en/ Media contact: [email protected] Investor contact: [email protected]

    2/9/26 4:16:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

    OMNY-AF pilot study reports 90% 12-month freedom from AFib with zero procedure-related adverse eventsi Additional data presented further reinforces the favorable and consistent safety and efficiency profile of the VARIPULSE platformii,iii,iv,v Johnson & Johnson today announced 12-month pilot-phase data from the OMNY-AF study, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation (AFib), during the 31st Annual AF Symposium in Boston. Initial results for 12-month outcomes across the 30-patient pilot cohort show investigators achieved 100% acute procedural success with no procedure-associated adverse events, while 56.7% of cases w

    2/6/26 7:00:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABMD
    $JNJ
    $SMCI
    $STLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Exec VP, CFO Wolk Joseph J

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    2/11/26 8:47:26 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, WWC. Innovative Medicine Taubert Jennifer L

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    2/11/26 8:45:44 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, CIO Swanson James D.

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    2/11/26 8:43:19 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABMD
    $JNJ
    $SMCI
    $STLD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABMD
    $JNJ
    $SMCI
    $STLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Johnson & Johnson from Equal-Weight to Overweight and set a new price target of $262.00

    1/28/26 7:11:28 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Super Micro Computer with a new price target

    Goldman resumed coverage of Super Micro Computer with a rating of Sell and set a new price target of $26.00

    1/13/26 9:18:14 AM ET
    $SMCI
    Computer Manufacturing
    Technology

    Steel Dynamics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Steel Dynamics from Overweight to Equal-Weight and set a new price target of $194.00

    1/9/26 8:52:20 AM ET
    $STLD
    Steel/Iron Ore
    Industrials

    $ABMD
    $JNJ
    $SMCI
    $STLD
    SEC Filings

    View All

    SEC Form S-3ASR filed by Johnson & Johnson

    S-3ASR - JOHNSON & JOHNSON (0000200406) (Filer)

    2/11/26 5:24:20 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Johnson & Johnson

    10-K - JOHNSON & JOHNSON (0000200406) (Filer)

    2/11/26 4:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Super Micro Computer Inc.

    10-Q - Super Micro Computer, Inc. (0001375365) (Filer)

    2/6/26 5:03:49 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    $ABMD
    $JNJ
    $SMCI
    $STLD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/12/24 5:27:36 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chan Shiu Leung bought $1,136,000 worth of shares (2,000 units at $568.00), increasing direct ownership by 5% to 42,917 units (SEC Form 4)

    4 - Super Micro Computer, Inc. (0001375365) (Issuer)

    2/5/24 4:33:58 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    $ABMD
    $JNJ
    $SMCI
    $STLD
    Leadership Updates

    Live Leadership Updates

    View All

    Steel Dynamics Announces Leadership Appointment

    FORT WAYNE, Ind., Nov. 11, 2025 /PRNewswire/ -- Steel Dynamics, Inc. (NASDAQ/GS: STLD) today announced the appointment of Matt Bell as the company's head of its metals recycling platform effective today. "I am excited and pleased to recognize Matt for his outstanding leadership and positive impact within our company," said Mark D. Millett, Chairman and Chief Executive Officer. "Since joining us in 2016, Matt's commercial and operational experience has helped lead our metals recycling teams to higher levels of service, efficiency, supply-chain solutions, and excellence. I am pl

    11/11/25 9:30:00 AM ET
    $STLD
    Steel/Iron Ore
    Industrials

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABMD
    $JNJ
    $SMCI
    $STLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Super Micro Computer Inc.

    SC 13G - Super Micro Computer, Inc. (0001375365) (Subject)

    11/14/24 12:52:53 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Super Micro Computer Inc. (Amendment)

    SC 13G/A - Super Micro Computer, Inc. (0001375365) (Subject)

    4/10/24 2:03:52 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    $ABMD
    $JNJ
    $SMCI
    $STLD
    Financials

    Live finance-specific insights

    View All

    Supermicro Announces Second Quarter Fiscal Year 2026 Financial Results

    Super Micro Computer, Inc. (NASDAQ:SMCI) ("Supermicro" or the "Company"), a Total IT Solution Provider for AI, Cloud, Storage, and 5G/Edge, today announced unaudited financial results for its second quarter of fiscal year 2026 ended December 31, 2025. Second Quarter Fiscal Year 2026 Highlights Net sales of $12.7 billion versus $5.0 billion in Q1'26 and $5.7 billion in Q2'25 Gross margin of 6.3% versus 9.3% in Q1'26 and 11.8% in Q2'25 Net income of $401 million versus $168 million in Q1'26 and $321 million in Q2'25 Diluted net income per common share of $0.60 versus $0.26 in Q1'26 and $0.51 in Q2'25 Non-GAAP gross margin of 6.4% versus 11.9% in Q2'25 Non-GAAP diluted net

    2/3/26 4:51:00 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    Steel Dynamics Reports Fourth Quarter and Annual 2025 Results

    FORT WAYNE, Ind., Jan. 26, 2026 /PRNewswire/ -- Annual 2025 Performance Highlights: Successful production and qualifications of industrial, beverage can, and automotive quality flat rolled aluminum productsSuccessful production and consumption of biocarbon materialRecord steel shipments of 13.7 million tonsNet sales of $18.2 billion, operating income of $1.5 billion, and net income of $1.2 billionAdjusted EBITDA of $2.2 billion and cash flow from operations of $1.4 billionLiquidity of over $2.2 billionShare repurchases of $901 million of the company's common stock, representin

    1/26/26 7:00:00 AM ET
    $STLD
    Steel/Iron Ore
    Industrials

    Supermicro to Report Second Quarter Fiscal 2026 Financial Results on February 3rd, 2026

    Super Micro Computer, Inc. (SMCI), a Total IT Solution Provider for AI/ML, HPC, Cloud, Storage, and 5G/Edge, today announced that it will host its second quarter fiscal 2026 financial results conference call on Tuesday, February 3rd, 2026, at 5:00 p.m. ET / 2:00 p.m. PT. The webcast will be available at https://ir.supermicro.com. A replay of the webcast will be available shortly after the call at the same website and will remain accessible for one year. About Super Micro Computer, Inc. Supermicro (NASDAQ:SMCI) is a global leader in Application-Optimized Total IT Solutions. Founded and operating in San Jose, California, Supermicro is committed to delivering first-to-market innovation

    1/22/26 4:31:00 PM ET
    $SMCI
    Computer Manufacturing
    Technology